In Brief: Glaxo Wellcome's Retrovir
Executive Summary
Glaxo Wellcome's Retrovir: New strengths of AZT would enable harmonization of Retrovir and Glaxo's Epivir dosing schedules: Retrovir is currently labeled for administration three times daily, while Epivir is dosed twice daily. AZT in a 300 mg tablet became "approvable" at FDA on Dec. 19; a 200 mg AZT tablet was approved the same day but is not yet marketed. Retrovir regimens typically total 500-600 mg per day. Retrovir has been available in 100 mg capsules and syrup...